血小板糖蛋白特异性抗体在骨髓增生异常综合征患者中的表达及其意义  

Expression of Specific Antibodies against Platelet Glycoproteins in Patients with MDS and Its Significance

作　　者：王涓冬[1] 潘祥林[1] 尹哲[1] 孙俊华[1] 孔桂香[2] 陈颖洁[3] 姜翠英[3] 窦爱霞[1] 王志仑[1] 

机构地区：[1]山东大学第二医院血液内科,济南250033 [2]山东大学第二医院产科,济南250033 [3]山东大学第二医院检验科,济南250033

出　　处：《中国实验血液学杂志》2007年第1期95-98,共4页Journal of Experimental Hematology

摘　　要：本研究探讨血小板糖蛋白特异性抗体在骨髓增生异常综合征(MDS)患者发病中的作用。采用改良的MAIPA法检测血浆血小板糖蛋白特异性抗体(抗GPⅡb/Ⅲa抗体和抗GPⅠb/Ⅸ抗体)。若患者的OD值大于正常OD值的均数+3倍标准差则为阳性。结果表明:MDS组总阳性率为16.67%(5/30),ITP组总阳性率为46.67%(14/30),两者之间差异有显著性(P<0.05)。结论:部分MDS患者的糖蛋白特异性抗体为阳性,这表明部分MDS患者的血小板减少与免疫因素有关;血小板糖蛋白特异性抗体所致的血小板破坏在MDS患者的血小板减少中可能具有一定作用,这为MDS患者的免疫抑制剂治疗提供了新的依据。The aim of this study was to find platelet specific autoantibodies against glycoproteins in myelodysplastic syndrome （ MDS ） and to explore its role in pathogenesis of MDS. The plasma autoantibodies against GP Ⅱ b/Ⅲ a and GP Ⅰb/Ⅸ were measured by using a modified monoclonal antibody specific immobolization platelet antigens assay （ MAIPA）. Absorbance greater than mean value plus tripled standard deviation recorded from the normal controls were regarded as positive. The results indicated that the total positive rate in patients with MDS was 16.67% （5/30）, the total positive rate in patients with ITP was 46.67% （ 14/30）, the difference between MDS group and ITP group was significant （ P 〈 0.05 ）. It is concluded that partial patients with MDS have plasma specific autoantibodies against platelet GP Ⅱ b/Ⅲa and GPⅠb/Ⅸ, indicating correlation of thrombocytopeula of patients with immune factors and the autoantibody-mediated platelet destruction may be involved in the pathogenesis of MDS. It provides a new basis for immunosuppression therapy for MDS.

关 键 词：骨髓增生异常综合征 血小板特异性抗体 糖蛋白 

分 类 号：R733.7[医药卫生—肿瘤]